CR9444A - Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes - Google Patents

Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes

Info

Publication number
CR9444A
CR9444A CR9444A CR9444A CR9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A
Authority
CR
Costa Rica
Prior art keywords
alcohol
modulars
relates
treat
stimulating substances
Prior art date
Application number
CR9444A
Other languages
English (en)
Inventor
Jose Legarda Ibanez Juan
Original Assignee
Hythiam Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hythiam Inc filed Critical Hythiam Inc
Publication of CR9444A publication Critical patent/CR9444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a metodos y tratamientos para usar composiciones farmaceuticas a partir de una clase de compuestos que modulan selectivamente, directa o indirectamente, la actividad del canal de cloruro GABAA, para tratar el abuso de alcohol y/o substancias estimulantes. La presente invencion tambien se refiere a metodos y protocolos para aliviar los sintomas asociados con el abuso del alcohol y/o substancias estimulantes en un plan de tratamiento compresivo.
CR9444A 2005-04-21 2007-10-16 Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes CR9444A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/111,435 US20050192271A1 (en) 2003-07-15 2005-04-21 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse

Publications (1)

Publication Number Publication Date
CR9444A true CR9444A (es) 2008-02-20

Family

ID=37215204

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9444A CR9444A (es) 2005-04-21 2007-10-16 Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes

Country Status (17)

Country Link
US (3) US20050192271A1 (es)
EP (1) EP1742639B1 (es)
JP (1) JP2008536921A (es)
KR (1) KR20080004615A (es)
CN (1) CN101203225A (es)
AT (1) ATE539755T1 (es)
AU (1) AU2006240324B2 (es)
BR (1) BRPI0610038A2 (es)
CA (1) CA2605918A1 (es)
CR (1) CR9444A (es)
IL (1) IL186641A0 (es)
MX (1) MX2007012993A (es)
NO (1) NO20075562L (es)
NZ (1) NZ562585A (es)
RU (1) RU2007143053A (es)
WO (1) WO2006115743A2 (es)
ZA (1) ZA200709048B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
RU2468799C1 (ru) * 2011-08-03 2012-12-10 Общество с ограниченной ответственностью "Урал Крафт" Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов
EP3057596A4 (en) * 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US20200143922A1 (en) * 2016-06-03 2020-05-07 Yale University Methods and apparatus for predicting depression treatment outcomes
WO2019195813A1 (en) * 2018-04-06 2019-10-10 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
DE4123106A1 (de) * 1991-07-09 1993-01-14 Schering Ag Arzneimittel zur behandlung von entzugssymptomen
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
ATE298747T1 (de) * 1998-03-31 2005-07-15 Shionogi & Co Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
AU4100699A (en) 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6750235B1 (en) * 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for cocaine craving
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
KR100712570B1 (ko) * 2001-01-17 2007-05-02 하이디엄, 인크. 알콜 의존성 치료약의 제조에서 플루마제닐의 용도
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CN1327843C (zh) * 2001-02-15 2007-07-25 海萨姆有限公司 氟马西尼在用于可卡因依赖治疗药物制备中的应用
US20020150632A1 (en) * 2001-04-12 2002-10-17 Nick Scott Psychonutracological method for craving reduction in humans
FR2827172B1 (fr) * 2001-07-13 2004-07-02 Pf Medicament Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides
US20030176456A1 (en) * 2001-12-21 2003-09-18 June Harry L. Methods for reducing alcohol cravings in chronic alcoholics
US6740677B2 (en) * 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
DE602004029993D1 (de) * 2003-02-27 2010-12-23 Eisai R&D Man Co Ltd Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
JP2005332453A (ja) * 2004-05-19 2005-12-02 Hitachi Ltd 情報再生装置及び情報再生方法
US20060167723A1 (en) * 2005-01-21 2006-07-27 Berg L M Method of treating dependencies
AU2006235318A1 (en) 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence

Also Published As

Publication number Publication date
WO2006115743A2 (en) 2006-11-02
CA2605918A1 (en) 2006-11-02
KR20080004615A (ko) 2008-01-09
IL186641A0 (en) 2008-06-05
US20050192271A1 (en) 2005-09-01
EP1742639B1 (en) 2012-01-04
NZ562585A (en) 2010-04-30
US20090215751A1 (en) 2009-08-27
AU2006240324A1 (en) 2006-11-02
CN101203225A (zh) 2008-06-18
EP1742639A2 (en) 2007-01-17
ZA200709048B (en) 2008-09-25
ATE539755T1 (de) 2012-01-15
US20080207599A1 (en) 2008-08-28
EP1742639A4 (en) 2008-05-07
MX2007012993A (es) 2008-03-11
AU2006240324B2 (en) 2010-02-25
US7863267B2 (en) 2011-01-04
WO2006115743A3 (en) 2007-06-28
JP2008536921A (ja) 2008-09-11
NO20075562L (no) 2007-12-07
RU2007143053A (ru) 2009-05-27
BRPI0610038A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
NO20064924L (no) Eksperimenteringssikker doseringsform som innbefatter an adsorbent og et skadelig middel
BRPI0508390B8 (pt) uso de um anticorpo antagonista anti-ngf, bem como kit e composição farmacêutica para tratamento de dor de câncer de osso
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE554800T1 (de) Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CR9444A (es) Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)